Leerink Partnrs Analysts Raise Earnings Estimates for Edwards Lifesciences Co. (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Leerink Partnrs raised their Q3 2024 earnings estimates for shares of Edwards Lifesciences in a report released on Friday, April 26th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings of $0.71 per share for the quarter, up from their previous forecast of $0.70. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.71 EPS and Q1 2025 earnings at $0.72 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%.

Several other research firms have also weighed in on EW. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Citigroup raised their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $92.71.

Edwards Lifesciences Price Performance

NYSE:EW opened at $84.68 on Monday. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $90.23 and a 200 day simple moving average of $79.16. Edwards Lifesciences has a 1-year low of $60.57 and a 1-year high of $96.12. The stock has a market capitalization of $50.97 billion, a PE ratio of 36.50, a P/E/G ratio of 4.28 and a beta of 1.05.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in EW. DSM Capital Partners LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $34,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $34,000. Pingora Partners LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $38,000. Finally, Operose Advisors LLC increased its position in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 452 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,250 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total transaction of $622,050.00. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Scott B. Ullem sold 7,250 shares of the business’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the completion of the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The disclosure for this sale can be found here. Insiders sold a total of 201,254 shares of company stock valued at $17,788,304 over the last quarter. 1.27% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.